Assessment of the Safety and Efficacy of a New Thrombolytic Regimen - ASSENT 3 PLUS


The goal of the ASSENT 3 PLUS trial was to examine the use of the low molecular weight heparin enoxaparin versus unfractionated heparin in combination with TNK in the pre-hospital setting for ST-segment elevation myocardial infarction (STEMI).